Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RegeneRx Biopharmaceuticals has received a patent, in Australia using thymosin beta 4 (Tß4) for the treatment of a broad array of gastrointestinal infections and disorders.
Subscribe to our email newsletter
The company said that the new patent will expire in 2023.
RegeneRx claims that it holds patents and patent applications worldwide related to its products and holds an exclusive worldwide license from the National Institutes of Health, as well as other licenses related to Tß4.
RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair and regeneration.
RegeneRx currently has three products in clinical development, RGN-352, RGN-259, RGN-137.